CAS: 14548-38-0; 6-Chloro-2,3-Dihydroinden-1-One

相似化合物

42348-86-7 68755-31-7 15115-59-0

上下游产品

CAS号201230-82-2 carbon monoxide | CAS号78704-49-1 (4-氯苯炔基)三甲基硅烷 | CAS号2019-34-3 3-(4-氯苯基)丙酸 | CAS号69975-65-1 6-氨基-1-茚酮 | CAS号1615-02-7 4-氯肉桂酸 | CAS号104-88-1 对氯苯甲醛 | CAS号174265-12-4 2-溴-5-氯苯甲醛 | CAS号1313762-49-0 1-bromo-4-chlor... | CAS号89-20-3 4-氯邻苯二酸 | CAS号77605-68-6 7-chloro-1-phen... | CAS号3970-51-2 5-氯-1H-茚 | CAS号52085-98-0 6-氯-2,3-二氢-茚-1-醇

对氯肉桂酸置于草酰氯,Palladium On Activated Charcoal,氢气体系中,用 二氯甲烷,乙酸乙酯 用作溶剂,化学反应 24.0H,反应生成6-氯-1-茚满酮
参考文献: Carbamate Derivative Compounds,Processes For Preparing Them And Their Uses[fr] Composés De Dérivés De Carbamate,Leurs Procédés De Préparation Et Leurs Utilisations
标题: Carbamate Derivative Compounds,Processes For Preparing Them And Their Uses[fr] Composés De Dérivés De Carbamate,Leurs Procédés De Préparation Et Leurs Utilisations
摘要:本发明涉及一种治疗或预防中枢神经系统疾病的药物组合物,其包含羰酸酯衍生物化合物和/或其药用可接受的盐作为活性成分.此外,本发明涉及一种治疗或预防中枢神经系统疾病的方法,包括向需要治疗或预防中枢神经系统疾病的受试者施用一种羰酸酯衍生物化合物的药用有效量.

专利信息

专利号:US-12006301-B1
优先权日:2021-05-13
标题 :And synthesis of dual 5-HT1A and 5-HT7 receptor ligands
发明人：ABLORDEPPEY SETH Y
权利人:FLORIDA A&M UNIV
摘要:Novel dual 5-HT1A and 5-HT7 receptor ligands and methods of using the novel ligands to treat a neurological disorder are presented.

专利号:US-9309165-B2
优先权日:2012-12-19
标 题 :6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
发明人：JACOBSEN MIKKEL FOG; BRANDES SEBASTIAN
权利人:LUNDBECK & CO AS H
摘要:The present invention discloses the compound 6-chloro-3-(phenyl-d 5 )-inden-1-one (I) and routes of synthesis to obtain (I). In a further aspect the present invention discloses the use of (I) for the synthesis of (S)-6-chloro-3-(phenyl-d 5 )-indan-1-one.

专利号:US-6316437-B1
优先权日:1999-09-30
标题:Spirohydantoin compounds and uses thereof
发明人：HOFFMAN JACOB M
权利人:MERCK & CO INC
摘要:Spirohydantoin compounds and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:US-2023002426-A1
优先权日:2019-11-15
标题 :Chiral synthesis of a tertiary alcohol

专利号:WO-2021097139-A1
优先权日:2019-11-15
标 题 :Chiral synthesis of a tertiary alcohol

专利号:WO-2015088564-A1
优先权日:2013-12-13
标 题:P2x4 receptor modulating compounds
发明人：NEWCOM JASON S; SPEAR KERRY L
权利人:SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are P2X4 receptor modulating compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including but not limited to, chronic pain, neuropathy, inflammatory diseases and central nervous system disorders.